



KRYSTEXXA REFERRAL FORM

RETURN COMPLETED
FORM VIA FAX TO:
888.898.9113

PATIENT INFORMATION (Complete or fax existing chart)	PRESCRIBER INFORMATION
Patient Name _____	Prescriber Name: _____
Address _____	State License: _____ NPI #: _____
City, State, Zip _____	DEA: _____ Phone: _____
Phone _____ ALT Phone: _____	Specialty _____ Fax: _____
DOB: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female _____	Address: _____
Weight: _____ HT: _____	City, State, Zip _____
Allergies: _____	Contact Person: _____ Phone: _____

INSURANCE INFORMATION - OR - Send a copy of the patient's prescription / insurance cards (front & back)	
Primary Insurance: _____	RX Card (PBM): _____
City, State, Zip _____	BIN: _____ PCN: _____
Plan #: _____ Group #: _____	City, State, Zip _____
Phone: _____	Group #: _____ Phone: _____

DIAGNOSIS / CLINICAL INFORMATION
Diagnosis: _____ ICD-10 Code(s): _____

KRYSTEXXA® INFUSION ORDERS	
Dose / Schedule	8 mg given as an intravenous infusion every 2 weeks
Labs prior to first treatment	Glucose-6-phosphate dehydrogenase (G6PD) deficiency.
Labs prior to each treatment	<input type="checkbox"/> sUA ~ NOTIFY physician if 2 consecutive serum uric acid levels are over 6 mg/dL - sUA test, preferably within 48 hours of the infusion.
Treatment	Minimum 2-hours infusion via gravity feed, syringe-type pump, infusion pump and 1-hour post infusion observation time
NaCl	250 mL Krystexxa can be infused in normal saline (0.9% NS) or half-normal saline (0.45% NS)
** DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS. USE ASEPTIC TECHNIQUE. **	

PREMEDICATIONS			
CLASS	DRUG(S)	DOSING	TIMING IN RELATION TO INFUSION
IV corticosteroids *†	<input type="checkbox"/> 80 mg methylprednisolone <input type="checkbox"/> 200 mg hydrocortisone Other: _____	Or dose determined by healthcare provider	Prior to each infusion
Antihistamines *†	<input type="checkbox"/> 60 mg fexofenadine <input type="checkbox"/> 50 mg diphenhydramine <input type="checkbox"/> Other: _____	Or dose determined by healthcare provider	Night before infusion, and/or can administer concomitantly with infusion
Oral analgesic *†	<input type="checkbox"/> 1000 mg acetaminophen	Or dose determined by healthcare provider	Prior to each infusion

In the event of anaphylaxis or infusion reaction, the infusion should be slowed, or stopped and restarted at a slower rate, at the discretion of the physician

GOUT FLARE PROPHYLAXIS			
CLASS	DRUG(S)	DOSING	TIMING IN RELATION TO INFUSION
Anti-gout flare agent	Colcrys® (colchicine)	Dose determined by healthcare provider Patient may take any one of these drugs, as indicated	Daily, treatment initiated 1 week prior to initiation of Krystexxa and lasting at least 6 months, unless medically contraindicated or not tolerated
Oral NSAIDs	Advil®, Aleve®		
Corticosteroids	Prednisone, prednisolone		

* To be given to the patient by nurse on the day of infusion.
† Infusion reaction may occur despite pretreatment.

Inform patients of the symptoms and signs of anaphylaxis and instruct them to seek immediate medical care should anaphylaxis occur after discharge from the healthcare setting.

PHYSICIAN'S SIGNATURE
X _____ Date: _____
Physician's Signature

Important Information: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.